PubMed Health⌕ Search

Biomedical subjects

C M Rose

Publications and source records attributed to C M Rose.

41 records · Page 3Linked to original sources
PubMed1979

A comparison of two technetium-99m-labeled radiopharmaceuticals for lymphoscintigraphy: concise communication.

A comparison of stannous phytate and antimony sulfide colloid, both labeled with Tc-99m, was conducted during the performance of internal mammary lymphoscintigraphy in 46 patients. Thirteen of these patients were randomized to receive both radiotracers in two consecutive studies. The results indicated a statistical difference between agents; Tc-99m antimony sulfide allowed visualization of a greater number of more intense nodes, better delineation of the total length of the internal mammary lymph-node chain, and a more consistent visualization of supraclavicular nodes. Although previously published animal data suggest utility of Tc-99m stannous phytate for lymph-node imaging, Tc-99m antimony sulfide was shown in this clinical comparison to provide a more reliable representation of lymph-node anatomy.

Antimony↗
PubMed1967

Daily rhythm in tyrosine concentration in human plasma: persistence on low-protein diets.

The concentration of tyrosine in the plasma of normal males varies diurnally. It is lowest (9.5 +/- 0.35 micrograms per milliliter) between 0130 and 0230 hours and rises to a peak of 16.2 +/- 0.82 micrograms per milliliter by 1030 hours. This rhythm persists when subjects are maintained for 2 weeks on a diet that is very low in protein.

17-Hydroxycorticosteroids↗
PubMedDate not supplied

Evidence for macrophage involvement in the enhancement of tumor growth delay with X-ray/Fluosol-DAR/O2 combination therapy.

The perfluorochemical emulsion, Fluosol-DAR, in combination with breathing a 95% oxygen atmosphere, has been shown to enhance the response of several solid tumors to radiation treatment. In this study, the number of macrophages present in two murine tumors was assessed in the absence of Fluosol-DA treatment and at various times post-Fluosol-DA treatment using a rosetting assay. The number of macrophages in the Lewis lung carcinoma and the FSaII fibrosarcoma, after an initial decrease, increased nearly 2-fold (at 14 days) after a single Fluosol-DA injection. Tumor response was assessed by tumor growth delay and excisional tumor cell survival assays in two tumor systems. Greater dose modifying effects were consistently observed when tumors remained in situ. Some animals were treated with carrageenan, a macrophage poison, prior to implantation of Lewis lung tumor. Animals treated with carrageenan, Fluosol-DA and carbogen prior to and during X-ray treatment exhibited a dose modifying factor (DMF) of 1.74 +/- 0.08. Animals treated similarly but without carrageenan pretreatment demonstrated a DMF of 2.61 +/- 0.22. Fluosol-DA administered 24 hours prior to carbogen breathing and X-rays resulted in a greater tumor growth delay than when the perflorochemical was injected immediately prior to radiation/carbogen treatment. The relatively nonimmunogenic FSaII tumor/C3H/Sed host system gave similar results but instead of dose modification, parallel displacements in the dose response curves were seen. Again, Fluosol-DA administrated 24 hours prior to radiation was more effective in sensitizing the tumor than immediate administration. These results suggest that Fluosol-DA in addition to functioning as an oxygen-carrier produces a nonspecific activation of the immune system.

Animals↗